MétaCan
Menu
← Back to cohort

The Use and Evaluation of Long-acting Injectable Antipsychotic Medications in Community-Dwelling Patients with Schizophrenia in Guangdong Province, China.

2024· editorial· en· W4403113262 on OpenAlexaboutno aff
Shi-Bin Wang, Wenyan Tan, Xiao-Yang Fu

Bibliographic record

VenuePubMed · 2024
Typeeditorial
Languageen
FieldMedicine
TopicSchizophrenia research and treatment
Canadian institutionsnot available
FundersGuangdong Medical Research Foundation
KeywordsSchizophrenia (object-oriented programming)ChinaAntipsychoticMedicinePsychiatryGeography

Abstract

fetched live from OpenAlex

Schizophrenia is a chronic, severe mental disorder with high disability and high recurrence, causing a serious burden to patients, their families, and society, and is an important public health problem.Most of the patients with schizophrenia live in the community, and antipsychotic maintenance treatment is essential to prevent recurrence.However, non-adherence to antipsychotic medications is one of the most important factors increasing relapses in schizophrenia, and nearly 60% of patients with schizophrenia are non-adherent to antipsychotic medications. 1 A systematic review and meta-analysis showed strong superiority of long-acting injectable antipsychotics (LAIs) in improving medication adherence and preventing recurrence compared to oral antipsychotics.2 In the past decade, developed countries like Canada, Australia, and the United States have widely used LAIs for patients with schizophrenia in communities, showing that they can improve patients' treatment compliance and social function and reduce violence and readmission rates.3 However, a study using data from 15 Asian countries/regions showed that the rate of use of LAIs to treat patients with schizophrenia in China is only 0.66%, far lower than the average of 15 countries/regions (17.9%).4 The regional variances in healthcare systems, such as availability of drugs, pharmaco-economics, and prescribing habits of psychiatrists, may play a role in the low rate of use of LAIs.In China, health insurance does not fully cover the cost of LAIs, so the higher price, poorer accessibility of LAIs, and lower socioeconomic level of the patients with schizophrenia could hinder using LAIs.5 Recommendation and Policy Support of Long-acting Injectables in ChinaAccording to the Guidelines for the Management and Treatment of Severe Mental Disorders (2018 edition) issued by the Chinese National Health Commission, LAIs were recommended for patients with poor treatment compliance, poor home care or no caregiver, or high risk of suicides and accidents.6 The Chinese Schizophrenia Coordination Group, Chinese Society of Psychiatry, and Chinese Society of General Practice established an expert group and developed a consensus on LAIs in the treatment of community-dwelling patients with schizophrenia in 2020, and put forward evidence-based recommendations on their clinical use.7 However, most psychiatrists and general practitioners still lack training on using LAIs antipsychotics in China and worry that the side effects of injection treatment may impede their spread and application.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Editorial · Consensus signal: none
Teacher disagreement score0.109
Threshold uncertainty score0.216

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0010.002
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.305
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes1
Has abstractyes

Explore more

Same venuePubMed→Same topicSchizophrenia research and treatment→French-language works237,207→